| Embryonic origin | mesoderm |
| Epidemiology | the most common pediatric soft tissue sarcoma (5 to 8% of all malignancies in childhood): annual incidence is 4/106; E-RMS accounts for 75% of all RMS, and is observed in young children (3-12 yrs); A-RMS is found in the remaining 25 %, and is observed in older children and young adults (6-21 yrs) |
| Clinics | E-RMS occurs predominantly in the head and neck region, the genito-urinary tract, and the retroperitoneum;
A-RMS occurs predominantly in the extremities and the trunk;
RMS often present as a tumour mass, or may be discovered from symptomsaccording |
| Pathology | in E-RMS, tumor cells are round or spindle-shaped and may exhibit various degrees of muscular differentiation; they are often dispersed in an abundant myxoid stroma; the botryoid type, observed in tumors developped in mucosa-lined organs (vagina, bladder), exhibits a polypoid grape-like pattern. in A-RMS, tumor cells are round and more dense than in E-RMS and, typically, they are arranged according a pattern reminiscent of lung alveoli. |
| Prognosis | dependent on the extent of disease at time of diagnosis, and on the type of RMS; patients with A-RMS have a poorer survival than those with E-RMS |
Cytogenetics
Morphological | E-RMS do not show recurrent structural chromosome rearrangement; the majority of the tumors are hyperdiploid, with an increased copy number for chromosomes 2, 7, 8, 12, and 13, in particular; comparative genomic hybridization (CGH) confirms these findings, showing gains of a variety of whole chromosomes, 2, 13, 12, 8, and 7 (in 50-60% of the cases), 17, 18, and 19 (40%), and the loss of chromosomes 16 and 10 (in 30-40%), and 15 and 14 (20%); polymorphism studies shows that E-RMS is associated with the loss of heterozygosity at 11p13. A-RMS is characterized by two pathognomonic translocations:
- t(2;13)(q35;q14) and
- t(1;13)(p36;q14), found in 80 and 15% of the cases respectively,
leading to the formation of gene fusions, namely
- PAX3 - FKHR, in the t(2;13), and
- PAX7 - FKHR in the t(1;13), generating fusion transcripts;
double-minute chromosomes have been reported in some RMS, and CGH has showed a high frequency of genomic amplifications; the amplicons are located in 12q13-15 (50% of the cases), 2p24 (36%), 13q14, 13q32, and 1q36 (14%), 1q21 and 8q13-q21 (7%);
the 12q13-15 amplicon could involve genes:
- CHOP,
- MDM2, and
- SAS;
- MYCN gene is amplified in cases with the amplicon at 2p24, but unlike in neuroblastoma, no correlation with prognosis seems to exist in RMS; cases with the fusion PAX7-FKHR often show an amplification of the fusion gene (and more frequently than cases with the PAX3-FKHR gene do). |
| Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. |
| Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ 3rd, Emanuel BS, Rovera G, Barr FG |
| Nature genetics. 1993 ; 5 (3) : 230-235. |
| PMID 8275086 |
| |
| Agreement among and within groups of pathologists in the classification of rhabdomyosarcoma and related childhood sarcomas. Report of an international study of four pathology classifications. |
| Asmar L, Gehan EA, Newton WA, Webber BL, Marsden HB, van Unnik AJ, Hamoudi AB, Shimada H, Tsokos M, Harms D |
| Cancer. 1994 ; 74 (9) : 2579-2588. |
| PMID 7923014 |
| |
| A new highly polymorphic DNA restriction site marker in the 5' region of the human tyrosine hydroxylase gene (TH) detecting loss of heterozygosity in human embryonal rhabdomyosarcoma. |
| Besnard-Guˆ©rin C, Cavenee WK, Newsham I |
| Human genetics. 1994 ; 93 (3) : 349-350. |
| PMID 7510263 |
| |
| Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. |
| Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG |
| Cancer research. 1994 ; 54 (11) : 2869-2872. |
| PMID 8187070 |
| |
| MYCN gene amplification in rhabdomyosarcoma. |
| Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J |
| Cancer. 1994 ; 73 (8) : 2231-2237. |
| PMID 8156531 |
| |
| - |
| Sandberg AA and Bridge JA |
| RG Landes Company.. |
| |
| MYCN gene amplification in rhabdomyosarcoma. |
| Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J |
| Cancer. 1994 ; 73 (8) : 2231-2237. |
| PMID 8156531 |
| |
| The molecular pathology of small round-cell tumours--relevance to diagnosis, prognosis, and classification. |
| McManus AP, Gusterson BA, Pinkerton CR, Shipley JM |
| The Journal of pathology. 1996 ; 178 (2) : 116-121. |
| PMID 8683375 |
| |
| MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). |
| Meddeb M, Valent A, Danglot G, Nguyen VC, Duverger A, Fouquet F, Terrier-Lacombe MJ, Oberlin O, Bernheim A |
| Cytogenetics and cell genetics. 1996 ; 73 (4) : 325-330. |
| PMID 8751388 |
| |
| Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. |
| Weber-Hall S, McManus A, Anderson J, Nojima T, Abe S, Pritchard-Jones K, Shipley J |
| Genes, chromosomes & cancer. 1996 ; 17 (1) : 7-13. |
| PMID 8889501 |
| |
| Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. |
| Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, Pritchard-Jones K, Shipley J |
| Cancer research. 1996 ; 56 (14) : 3220-3224. |
| PMID 8764111 |
| |
